BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Exemestane

Protocol Code: BRAVEXE

Tumour Group: Breast

Contact Physician: Dr. Susan Ellard

ELIGIBILITY:
- hormonal treatment for hormone receptor positive advanced breast cancer in postmenopausal women
- consideration should first be given to using BRAVEVEX for fit patients after recurrence or progression on a non-steroidal aromatase inhibitor (anastrozole or letrozole).

EXCLUSION CRITERIA:
- Premenopausal women.

TESTS:
- None required.

TREATMENT:
- Exemestane 25 mg po daily until evidence of progression.

Contact Dr. Susan Ellard or tumour group delegate at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.

Date Activated: 01 July 2001
Date Revised: 01 May 2014 (Minor typo corrected)

REFERENCES: